Saint Kitts and Nevis

Medicines and pharmaceutical services in Saint Kitts and Nevis are overseen through the Ministry of Health and the national public-health system. A PAHO pharmaceutical country profile describes the national pharmaceutical sector and Ministry responsibilities, while regional medicines-safety cooperation is supported through CARPHA’s VigiCarib network, which accepts suspected adverse reactions, adverse events following immunization, and pharmaceutical quality reports from CARPHA Member States and routes them to the relevant country office. Publicly available national sources do not establish a detailed, industry-facing pharmacovigilance code imposing blanket requirements on every marketing authorisation Holder (MAH) to appoint a resident QPPV, maintain a local PSMF, or follow defined national ICSR and periodic-reporting schedules. Companies importing or supplying medicines should therefore confirm product-specific conditions with the Ministry, maintain a documented global safety system and accessible local safety contact, and establish procedures for collecting, evaluating, following up, and promptly communicating serious or unexpected adverse reactions, product-quality issues, medication errors, recalls, and other urgent safety information through national or VigiCarib channels. Where the cited public sources do not expressly define periodic safety reporting, risk-management plan, signal management and audit and inspection arrangements, the MAH should confirm the current product-specific requirements with the competent authority and against the marketing-authorisation conditions. BAUPHARMA supporting resources (operational context only, not national regulatory evidence): Effective Signal Management in Pharmacovigilance.